CSIMarket
 


Monopar Therapeutics Inc   (MNPR)
Other Ticker:  
 

Monopar Therapeutics Inc 's Working Capital Ratio

MNPR's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Current Liabilities decreased faster than Monopar Therapeutics Inc 's Current Assets, this led to improvement in Monopar Therapeutics Inc 's Working Capital Ratio to 4.32, Working Capital Ratio remained below Monopar Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 168 other companies have achieved higher Working Capital Ratio than Monopar Therapeutics Inc in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 710, from total ranking in the second quarter 2023 at 834.

Explain Working Capital Ratio
How much in Current Assets MNPR´s has?
What is the value of MNPR´s Current Liabilities?


MNPR Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 3.53 % 14.4 % 168.85 % 97.96 % 54.39 %
Y / Y Current Assets Change -40.38 % -38.14 % -34.58 % -35.84 % -35.98 %
Working Capital Ratio MRQ 4.32 4.12 4.08 4.21 7.51
MNPR's Total Ranking # 710 # 834 # 1172 # 935 # 805
Seq. Current Liabilities Change -20.79 % -13.37 % -7.71 % 63.45 % -12.47 %
Seq. Current Assets Change -16.83 % -12.58 % -10.5 % -8.39 % -13.69 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 169
Healthcare Sector # 324
Overall Market # 710


Working Capital Ratio Statistics
High Average Low
22.1 10.18 4.08
(Jun 30 2021)   (Mar 31 2023)




Financial Statements
Monopar Therapeutics Inc 's Current Liabilities $ 2 Millions Visit MNPR's Balance sheet
Monopar Therapeutics Inc 's Current Assets $ 9 Millions Visit MNPR's Balance sheet
Source of MNPR's Sales Visit MNPR's Sales by Geography


Cumulative Monopar Therapeutics Inc 's Working Capital Ratio

MNPR's Working Capital Ratio for the trailling 12 Months

MNPR Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 3.53 % 14.4 % 168.85 % 97.96 % 54.39 %
Y / Y Current Assets TTM Growth -40.38 % -38.14 % -34.58 % -35.84 % -35.98 %
Working Capital Ratio TTM 4.17 4.76 5.53 7.49 10.3
Total Ranking TTM # 3879 # 2579 # 3995 # 3153 # 3135
Seq. Current Liabilities TTM Growth -20.79 % -13.37 % -7.71 % 63.45 % -12.47 %
Seq. Current Assets TTM Growth -16.83 % -12.58 % -10.5 % -8.39 % -13.69 %


On the trailing twelve months basis Due to decline in Current Liabilities in the III Quarter 2023 to $1.98 millions, cumulative Working Capital Ratio decreased to 4.17 below the Monopar Therapeutics Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 485 other companies have achieved higher Working Capital Ratio than Monopar Therapeutics Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2579 to 3879.

Explain Working Capital Ratio
How much in Current Assets MNPR´s has?
What is the value of MNPR´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 486
Healthcare Sector # 1014
Within the Market # 3879


trailing twelve months Working Capital Ratio Statistics
High Average Low
17.08 9.76 4.17
(Mar 31 2022)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Sensei Biotherapeutics Inc   11.86 $ 73.836  Millions$ 6.226  Millions
Mei Pharma Inc   11.78 $ 88.422  Millions$ 7.509  Millions
Ventyx Biosciences Inc   11.76 $ 308.092  Millions$ 26.208  Millions
Protagonist Therapeutics inc   11.66 $ 324.881  Millions$ 27.867  Millions
Cormedix Inc   11.61 $ 89.062  Millions$ 7.671  Millions
Erasca Inc   11.45 $ 305.966  Millions$ 26.730  Millions
Anaptysbio Inc   11.43 $ 428.000  Millions$ 37.437  Millions
Uniqure N v   11.42 $ 693.626  Millions$ 60.719  Millions
Avidity Biosciences Inc   11.40 $ 555.487  Millions$ 48.716  Millions
Caladrius Biosciences Inc   11.15 $ 57.233  Millions$ 5.132  Millions
Atai Life Sciences N v   11.12 $ 215.825  Millions$ 19.403  Millions
Pasithea Therapeutics Corp   11.11 $ 20.771  Millions$ 1.869  Millions
Lipocine Inc   10.98 $ 24.614  Millions$ 2.241  Millions
Nkarta Inc   10.97 $ 281.188  Millions$ 25.640  Millions
Kinnate Biopharma Inc   10.80 $ 170.301  Millions$ 15.774  Millions
Virios Therapeutics Inc   10.77 $ 5.249  Millions$ 0.487  Millions
Xencor Inc  10.77 $ 571.176  Millions$ 53.041  Millions
Xenetic Biosciences Inc   10.53 $ 11.257  Millions$ 1.069  Millions
Actinium Pharmaceuticals Inc   10.50 $ 85.596  Millions$ 8.150  Millions
Milestone Pharmaceuticals inc   10.45 $ 84.797  Millions$ 8.114  Millions
Structure Therapeutics Inc   10.45 $ 209.959  Millions$ 20.091  Millions
Lianbio  10.06 $ 257.805  Millions$ 25.627  Millions
Annexon Inc   9.85 $ 169.169  Millions$ 17.170  Millions
Scpharmaceuticals Inc   9.75 $ 104.339  Millions$ 10.703  Millions
Syndax Pharmaceuticals Inc   9.73 $ 380.974  Millions$ 39.174  Millions
Werewolf Therapeutics Inc   9.64 $ 139.258  Millions$ 14.439  Millions
Tff Pharmaceuticals Inc   9.54 $ 10.893  Millions$ 1.142  Millions
Amylyx Pharmaceuticals Inc   9.52 $ 434.110  Millions$ 45.617  Millions
Centessa Pharmaceuticals Plc  9.51 $ 332.453  Millions$ 34.954  Millions
Reneo Pharmaceuticals Inc   9.49 $ 128.772  Millions$ 13.563  Millions

Date modified: 2023-11-12T07:52:52+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com